Logo of aacPermissionsJournals.ASM.orgJournalAAC ArticleJournal InfoAuthorsReviewers
Antimicrob Agents Chemother. Jun 1991; 35(6): 1181–1185.
PMCID: PMC284307

In vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to sparfloxacin and PD 127391.


The in vitro activities of two investigational quinolones, sparfloxacin (previously designated AT 4140) and PD 127391, were determined for 30 strains each of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum and compared with those of ciprofloxacin, tetracycline, clindamycin, and erythromycin. Erythromycin was the most active compound against M. pneumoniae (maximum MIC, less than 0.008 microgram/ml). PD 127391 (MICs, less than 0.008 to 0.031 microgram/ml), sparfloxacin (MICs, less than 0.008 to 0.25 microgram/ml), clindamycin (MICs, less than 0.008 to 0.5 microgram/ml), and tetracycline (MICs, 0.063 to 0.25 microgram/ml) were superior to ciprofloxacin (MICs, 0.5 to 2 microgram/ml). Sparfloxacin and PD 127391 were active against M. hominis (MICs, less than 0.008 to 0.031 microgram/ml for each) at concentrations comparable to those of clindamycin (MICs, less than 0.008 to 0.063 microgram/ml) and at concentrations lower than those of ciprofloxacin (MICs, 0.125 to 0.5 microgram/ml). As expected, M. hominis was resistant to erythromycin (MICs, 32 to greater than or equal to 256 micrograms/ml). For U. urealyticum, PD 127391 (MICs, 0.031 to 0.5 microgram/ml) and sparfloxacin (MICs, 0.063 to 1 microgram/ml) were superior to erythromycin (MICs, 0.25 to 4 micrograms/ml), ciprofloxacin (MICs, 0.5 to 8 micrograms/ml), and clindamycin (MICs, 0.25 to 64 micrograms/ml. Both new quinolones were equally active against tetracycline-susceptible as well as resistant strains of M. hominis and U. urealyticum. The possible influence of medium components and/or pH on MICs was evaluated by testing a Staphylococcus aureus reference strain with each antibiotic in SP-4 broth and 10-B broth and comparing the results with published MICs for this strain. MICs determined in 10-B broth for erythromycin were affected most. This study shows that the activities of sparfloxacin and PD 127391 are similar to one another and comparable or superior to those of other drugs used to treat mycoplasmal infections. The MICs of both new quinolones were consistently 2 to several dilutions lower than those of ciprofloxacin for each species.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.1M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Aznar J, Caballero MC, Lozano MC, de Miguel C, Palomares JC, Perea EJ. Activities of new quinoline derivatives against genital pathogens. Antimicrob Agents Chemother. 1985 Jan;27(1):76–78. [PMC free article] [PubMed]
  • Cantet P, Renaudin H, Quentin C, Bebear C. Activité comparée in vitro de sept quinolones sur Ureaplasma urealyticum. Pathol Biol (Paris) 1983 Jun;31(6):501–503. [PubMed]
  • Cassell GH, Crouse DT, Waites KB, Rudd PT, Davis JK. Does Ureaplasma urealyticum cause respiratory disease in newborns? Pediatr Infect Dis J. 1988 Aug;7(8):535–541. [PubMed]
  • Cassell GH, Davis JK, Waites KB, Rudd PT, Talkington D, Crouse D, Horowitz SA. Pathogenesis and significance of urogenital mycoplasmal infections. Adv Exp Med Biol. 1987;224:93–115. [PubMed]
  • Cassell GH, Waites KB, Crouse DT, Rudd PT, Canupp KC, Stagno S, Cutter GR. Association of Ureaplasma urealyticum infection of the lower respiratory tract with chronic lung disease and death in very-low-birth-weight infants. Lancet. 1988 Jul 30;2(8605):240–245. [PubMed]
  • Cassell GH, Waites KB, Pate MS, Canupp KC, Duffy LB. Comparative susceptibility of Mycoplasma pneumoniae to erythromycin, ciprofloxacin, and lomefloxacin. Diagn Microbiol Infect Dis. 1989 Sep-Oct;12(5):433–435. [PubMed]
  • Cummings MC, McCormack WM. Increase in resistance of Mycoplasma hominis to tetracyclines. Antimicrob Agents Chemother. 1990 Dec;34(12):2297–2299. [PMC free article] [PubMed]
  • Dobson RA, O'Connor JR, Poulin SA, Kundsin RB, Smith TF, Came PE. In vitro antimicrobial activity of rosoxacin against Neisseria gonorrhoeae, Chlamydia trachomatis, and Ureaplasma urealyticum. Antimicrob Agents Chemother. 1980 Nov;18(5):738–740. [PMC free article] [PubMed]
  • Evans RT, Taylor-Robinson D. The incidence of tetracycline-resistant strains of Ureaplasma urealyticum. J Antimicrob Chemother. 1978 Jan;4(1):57–63. [PubMed]
  • Fallon RJ, Brown WM. In-vitro sensitivity of legionellas, meningococci and mycoplasmas to ciprofloxacin and enoxacin. J Antimicrob Chemother. 1985 Jun;15(6):787–789. [PubMed]
  • Freeman S, Wormuth J, Cornett J. In vitro activity of amifloxacin against Chlamydia trachomatis and Ureaplasma urealyticum. Eur J Clin Microbiol. 1985 Oct;4(5):515–516. [PubMed]
  • Hoban D, DeGagne P, Witwicki E. In vitro activity of lomefloxacin against Chlamydia trachomatis, Neisseria gonorrhoeae, Haemophilus ducreyi, Mycoplasma hominis, and Ureaplasma urealyticum. Diagn Microbiol Infect Dis. 1989 May-Jun;12(3 Suppl):83S–86S. [PubMed]
  • Kenny GE, Cartwright FD. Susceptibility of Mycoplasma pneumoniae to several new quinolones, tetracycline, and erythromycin. Antimicrob Agents Chemother. 1991 Mar;35(3):587–589. [PMC free article] [PubMed]
  • Kenny GE, Hooton TM, Roberts MC, Cartwright FD, Hoyt J. Susceptibilities of genital mycoplasmas to the newer quinolones as determined by the agar dilution method. Antimicrob Agents Chemother. 1989 Jan;33(1):103–107. [PMC free article] [PubMed]
  • Krausse R, Ullmann U. Comparative in vitro activity of fleroxacin (RO 23-6240) against Ureaplasma urealyticum and Mycoplasma hominis. Eur J Clin Microbiol Infect Dis. 1988 Feb;7(1):67–69. [PubMed]
  • Liebowitz LD, Saunders J, Fehler G, Ballard RC, Koornhof HJ. In vitro activity of A-56619 (difloxacin), A-56620, and other new quinolone antimicrobial agents against genital pathogens. Antimicrob Agents Chemother. 1986 Dec;30(6):948–950. [PMC free article] [PubMed]
  • Lorian V, Sabath LD. Effect of pH on the activity of erythromycin against 500 isolates of gram-negative bacilli. Appl Microbiol. 1970 Nov;20(5):754–756. [PMC free article] [PubMed]
  • Mogabgab WJ, Holmes B, Murray M, Beville R, Lutz FB, Tack KJ. Randomized comparison of ofloxacin and doxycycline for chlamydia and ureaplasma urethritis and cervicitis. Chemotherapy. 1990;36(1):70–76. [PubMed]
  • Nakamura S, Minami A, Nakata K, Kurobe N, Kouno K, Sakaguchi Y, Kashimoto S, Yoshida H, Kojima T, Ohue T, et al. In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone. Antimicrob Agents Chemother. 1989 Aug;33(8):1167–1173. [PMC free article] [PubMed]
  • Osada Y, Ogawa H. Antimycoplasmal activity of ofloxacin (DL-8280). Antimicrob Agents Chemother. 1983 Mar;23(3):509–511. [PMC free article] [PubMed]
  • Renaudin H, Quentin C, de Barbeyrac B, Bebear C. Activité in vitro de nouvelles quinolones sur les mycoplasmes pathogènes pour l'homme. Pathol Biol (Paris) 1988 May;36(5):496–499. [PubMed]
  • Ridgway GL, Mumtaz G, Gabriel FG, Oriel JD. The activity of ciprofloxacin and other 4-quinolones against Chlamydia trachomatis and Mycoplasmas in vitro. Eur J Clin Microbiol. 1984 Aug;3(4):344–346. [PubMed]
  • Roberts MC, Kenny GE. TetM tetracycline-resistant determinants in Ureaplasma urealyticum. Pediatr Infect Dis. 1986 Nov-Dec;5(6 Suppl):S338–S340. [PubMed]
  • Shepard MC, Lunceford CD. Serological typing of Ureaplasma urealyticum isolates from urethritis patients by an agar growth inhibition method. J Clin Microbiol. 1978 Nov;8(5):566–574. [PMC free article] [PubMed]
  • Simon C, Lindner U. In vitro activity of norfloxacin against Mycoplasma hominis and Ureaplasma urealyticum. Eur J Clin Microbiol. 1983 Oct;2(5):479–480. [PubMed]
  • Taylor-Robinson D, Furr PM. Clinical antibiotic resistance of Ureaplasma urealyticum. Pediatr Infect Dis. 1986 Nov-Dec;5(6 Suppl):S335–S337. [PubMed]
  • Taylor-Robinson D, Furr PM, Webster AD. Ureaplasma urealyticum in the immunocompromised host. Pediatr Infect Dis. 1986 Nov-Dec;5(6 Suppl):S236–S238. [PubMed]
  • Tjiam KH, Wagenvoort JH, van Klingeren B, Piot P, Stolz E, Michel MF. In vitro activity of the two new 4-quinolones A56619 and A56620 against Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma hominis, Ureaplasma urealyticum and Gardnerella vaginalis. Eur J Clin Microbiol. 1986 Oct;5(5):498–501. [PubMed]
  • Tully JG. Laboratory diagnosis of Mycoplasma pneumoniae infections. Isr J Med Sci. 1981 Jul;17(7):644–647. [PubMed]
  • Waites KB, Cassell GH, Canupp KC, Fernandes PB. In vitro susceptibilities of mycoplasmas and ureaplasmas to new macrolides and aryl-fluoroquinolones. Antimicrob Agents Chemother. 1988 Oct;32(10):1500–1502. [PMC free article] [PubMed]
  • Waites KB, Figarola TA, Schmid T, Crabb DM, Duffy LB, Simecka JW. Comparison of agar versus broth dilution techniques for determining antibiotic susceptibilities of Ureaplasma urealyticum. Diagn Microbiol Infect Dis. 1991 May-Jun;14(3):265–271. [PubMed]
  • Waites KB, Rudd PT, Crouse DT, Canupp KC, Nelson KG, Ramsey C, Cassell GH. Chronic Ureaplasma urealyticum and Mycoplasma hominis infections of central nervous system in preterm infants. Lancet. 1988 Jan 2;1(8575-6):17–21. [PubMed]
  • Yancey RJ, Jr, Klein LK. In-vitro activity of trospectomycin sulphate against Mycoplasma and Ureaplasma species isolated from humans. J Antimicrob Chemother. 1988 Jun;21(6):731–736. [PubMed]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)


Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...